<DOC>
	<DOC>NCT01635517</DOC>
	<brief_summary>The aims of the present study are to investigate prospectively the clinical course and outcome of the hospitalized heart failure patients treated with tolvaptan for management of fluid retention and serum sodium levels of less than 140 mEq/L and also to analyze the factors related with the efficacy including outcome of tolvaptan therapy.</brief_summary>
	<brief_title>Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure</brief_title>
	<detailed_description>Vasopressin mediates fluid retention in heart failure. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise for management of heart failure.</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1. hospitalized patients for decompensated heart failure with signs of fluid retention despite using diuretics other than tolvaptan and planned tolvaptan use 2. serum Na &lt; 140 mEq/L 3. age: &gt; or = 20 years at the time of informed consent 4. provided written informed consent. 1. hemodynamic instability 2. patients with hypersensitivity to tolvaptan or similar compounds 3. anuric patients 4. patients who cannot feel thirst and are difficult to intake the fluid 5. patients who are pregnant, potentially pregnant or willing to be pregnant 6. patients have taken tolvaptan before enrollment after hospitalization 7. acute coronary syndrome 8. adrenal insufficiency 9. patients scheduled to undergo coronary angioplasty within the study period 10. ineligible patients according to the investigator's judgment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diuretics</keyword>
	<keyword>Vasopressins</keyword>
	<keyword>Sodium</keyword>
</DOC>